Product Overview

GW-0742 powder is a brandless research-grade compound chemically designated as 2-[4-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]acetic acid, provided exclusively for investigative laboratory purposes. It serves qualified analytical laboratories, pharmaceutical R&D facilities, and academic institutions requiring a verified PPARδ-selective reference material for in vitro binding assays, chromatographic method development, and structural analog studies. Each production batch meets or exceeds ≥98% purity specifications, supported by comprehensive analytical verification and lot-specific certificates of analysis (COAs) for laboratory quality integration.

Positioned as an unbranded generic reagent, GW-0742 powder supports non-clinical research workflows including nuclear receptor profiling, ligand displacement assays, and quantitative structure-activity relationship (QSAR) modeling. No references to therapeutic applications, biological testing beyond analytics, or administration protocols are intended or implied. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

GW-0742 is classified as a synthetic PPARδ agonist research chemical, functioning as an analytical reference standard in nuclear receptor pharmacology and metabolic pathway investigations. Its thiazole core and fluorinated substituents distinguish it within PPAR modulator analog series for laboratory characterization studies.

Key identifiers include:

• Synonyms: GW0742; GW 0742; GW 610742

• CAS number: 317318-84-6

• Molecular formula: C21H17F4NO3S2

• Molecular weight: 471.49 g/mol

These parameters enable precise inventory tracking in laboratory information management systems (LIMS), mass spectral library matching, and standardized documentation across research collaborations.​

Chemical & Physical Characteristics

GW-0742 powder presents as a white to off-white crystalline solid, engineered for optimal stability and handling in analytical powder form. The fine crystalline morphology facilitates accurate gravimetric preparation, dissolution into stock solutions, and aliquoting for high-throughput screening formats or calibration curves.

Solubility demonstrates excellent compatibility with DMSO (>47 mg/mL), ethanol (≥49 mg/mL with sonication), and DMF, supporting versatile formulation in cell-free assays, reporter gene systems, or liquid chromatography mobile phases. Limited aqueous solubility reflects its lipophilic character, requiring cosolvent strategies for buffered applications; empirical solubility profiling under specific pH and ionic strength conditions is recommended. Melting point ranges 134.5-135.5°C indicate thermal robustness for ambient manipulations, with density ~1.46 g/cm³ aiding volumetric conversions.

Purity & Analytical Verification

This GW-0742 powder guarantees ≥98% purity via orthogonal analytical confirmation including high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), nuclear magnetic resonance (NMR) spectroscopy, and UV-Vis spectrophotometry. Method suites quantify active pharmaceutical ingredient (API) content, resolve process-related impurities, assess counterion balance, and verify polymorphic form consistency against reference standards.

Detailed batch COAs report chromatographic purity (>98% main peak), mass-to-charge ratios matching theoretical monoisotopic mass, proton NMR chemical shifts aligning with structural assignments, and residual solvent headspace GC data compliant with ICH Q3C guidelines. These documents facilitate method transfer, proficiency testing, and accreditation audits in regulated research environments. Availability of raw spectral files supports in-house reprocessing for custom quantification workflows. Third-party validation laboratories provide independent orthogonality for multi-investigator studies.

Quality Control & Batch Integrity

Batch manufacturing employs unique lot serialization across primary packaging, COAs, and electronic records, establishing immutable traceability from raw material receipt through final release. Quality assurance encompasses vendor qualification for starting materials, in-process controls monitoring reaction kinetics and intermediate purifications, and release testing against predefined acceptance criteria for identity, potency, and physical form.​

Statistical release sampling per ICH Q4B annexes ensures representative lot homogeneity, with process capability indices (Cpk >1.33) tracking critical quality attributes over production campaigns. Retained engineering samples enable stability bridging and forced degradation profiling per ICH Q1B photostability protocols. Optional pharmacopeial testing against USP/EP infrared reference spectra supplements internal methods, enhancing documentation suitability for technology transfer or collaborative grant submissions. This rigorous paradigm minimizes analytical variability risks across serial procurements.

Safety, Handling & Laboratory Precautions

GW-0742 powder manipulation requires certified chemical fume hoods or containment enclosures operated by GLP-trained personnel to mitigate dust inhalation, dermal absorption, or ocular exposure risks. Core PPE includes layered nitrile gloves (8-15 mil), ANSI Z87.1-compliant goggles, Tyvek labwear, and N95 respirators for powder transfer operations exceeding 1 mg scale. Local exhaust ventilation maintains airborne concentrations below 50% OEL where established.​

Mandatory SDS review precedes use, delineating GHS classifications (H302, H315, H319, H335), incompatible materials (strong oxidants, mineral acids), and spill countermeasures integrating vermiculite absorption with 10% sodium bicarbonate neutralization. Hazardous waste streams segregate per RCRA/RC14001 protocols; autoclave decontamination precedes landfill disposition where permitted. No permissible exposure limits, acute reference doses, or clinical toxicology data are referenced or endorsed.

Packaging, Labeling & Storage

Primary containment features amber Type I glass vials with chlorobutyl rubber stoppers and flip-top aluminum crimp seals, imparting triple protection against hydrolytic catalysis, photoisomerization, and peroxide-induced oxidation. Desiccant sachets and Mylar bubblewrap secondary packaging fortify bulk shipments against thermal excursion and mechanical shock. Labels conform to GHS Rev. 9, displaying IUPAC nomenclature, CAS registry, lot expiry, supplemental PBT/vPvB assessments, and scannable DataMatrix codes linking to digital COA repositories.​

Storage at 2-8°C under low-humidity (<30% RH) conditions preserves chemical integrity over 36-month horizons; -20°C freezer excursion extends beyond-project timelines. Argon backfilling minimizes autoxidation of thioether linkages. Real-time release testing via HPLC monitors active content decay kinetics, informing requalification intervals. Physical segregation from alkalies, halogens, and heavy metal salts precludes adventitious complexation or precipitation events.

Intended Research Use & Market Positioning

GW-0742 powder enables PPARδ pharmacophore mapping, allosteric modulator hit expansion, fatty acid oxidation pathway interrogation, and high-content screening cascades in metabolic disease modeling platforms. Sub-nanomolar potency supports fluorescence polarization (FP) binding assays, time-resolved Förster resonance energy transfer (TR-FRET) coactivator recruitment, and isothermal titration calorimetry (ITC) thermodynamic profiling of ligand-receptor interactions.​

Exclusively designated as an analytical-grade reagent, it precludes designation for whole-organism models, human subject protocols, veterinary therapeutics, diagnostic kits, or IND-enabling safety pharmacology. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Ordering, Availability & Fulfillment

Available for immediate secure purchase via compliant eCommerce with dynamic pricing scaling from milligram research quantities to gram-scale production support. Integrated payment orchestration handles multi-currency transactions, automated KYC verification, and export license flagging per ITAR/EAR dual-use controls. Fulfillment executes within 48 hours using insulated parcel service with 2-8°C cold chain maintenance and RFID-tagged chain-of-custody manifests.​

Extended services include volumetric dispensing into LC autosampler arrays, 13C-D3 isotopomer pairing for LC-MS internal standardization, and lyophilized microdose packaging for direct infusion studies. Account specialists coordinate non-GxP technical support encompassing counterion exchange recommendations, amorphous dispersion feasibility, and salt screening matrices. Lot reservation protocols prioritize current-campaign material for standing purchase orders, stabilizing supply variance across multi-year investigations.

Legal & Regulatory Disclaimer

GW-0742 powder constitutes a bona fide research chemical absent FDA/EMA marketing authorizations, novel food approvals, dietary ingredient notifications, or cGMP certifications for pharmaceutical manufacture. No representations exist regarding residual DNA/RNA thresholds, endotoxin specifications, or elemental impurities compliance per ICH Q3D. Institutional purchasers affirm legitimate end-use declarations, possession licensing adequacy, and conformity to prevailing controlled substance schedules, REACH annexes, and TSCA inventory statuses as jurisdictionally mandated.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.